Tanespimycin (KOS-953, 17-AAG)

Brand Name:
Generic Name: tanespimycin
Code Names: KOS-953, 17-AAG
Company: Bristol-Myers Squibb / Kosan Biosciences
FDA Clinical Phase: 3

Description:
A benzoquinone antineoplastic antibiotic derived from the antineoplastic antibiotic geldanamycin. Tanespimycin binds to and inhibits the cytosolic chaperone functions of heat shock protein 90 (HSP90). HSP90 maintains the stability and functional shape of many oncogenic signaling proteins; the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be overexpressed by tumor cells.

Clinical Trials:
Currently, there are no open clinical trials studying tanespimycin for multiple myeloma.

Source:
NCI, Tanespimycin, http://www.ncipoet.com/Templates/drugdictionary.aspx?CdrID=43635 (as of May 22, 2009);
ClinicalTrials.gov, Multiple Myeloma AND Tanespimycin, http://www.clinicaltrial.gov/ct2/show/NCT00546780?term=multiple+myeloma+AND+Tanespimycin&rank=1 (as of November 14, 2009)

Related Articles:

Leave a comment

Add your comment below, or trackback from your own site. You can also subscribe to these comments via RSS.